Pepsinogen I (PGI)

Number: LD-PGI-01
Product description

Project Introduction

Pepsinogen Biological Properties

Pepsinogen (PG) is a precursor of pepsin, which is divided into two subgroups according to biochemical properties and immunogenicity, namely pepsinogen I (PGⅠ) and pepsinogen II (PGII). About 1% of pepsinogen enters the blood and exists stably. The content of PG I and PG II in serum reflects the number of glands and cells in the gastric mucosa, and also indirectly reflects the secretory function of different parts of the gastric mucosa. PG indicators have different degrees of changes in various gastric diseases, providing reliable diagnostic value for clinical practice.

Clinical significance of pepsinogen

There are two subtypes of pepsin, PGI and PGII, and their levels reflect the morphology and function of gastric mucosa in different parts. PGI is an indicator to detect the function of oxyntic gland cells. Gastric acid secretion increases and PGI increases, while secretion decreases or gastric mucosal gland atrophy decreases PGI; PGII has a greater correlation with gastric fundus mucosal lesions (relative to gastric antrum mucosa), and its increase Higher levels were associated with atrophy of fundic gland ducts, gastric epithelial metaplasia or pseudopyloric gland metaplasia, and atypia; the progressive decrease of PGI/II ratio was associated with the progression of gastric mucosal atrophy.

The development process of pepsinogen (PG) on gastric diseases can generally be expressed as superficial gastritis - gastric mucosal erosion ulcer - atrophic gastritis - gastric cancer, and other diseases have a good diagnosis and screening effect. PGⅠ/Ⅱ is used to detect the content of pepsinogen Ⅰ/Ⅱ in serum or plasma. Through the difference of its serum measurement value, there are different degrees of changes in various gastric diseases, providing reliable diagnostic value for clinical practice.

PG antigen

As predictive and monitoring indicators of atrophic gastritis and gastric cancer, PGI and the ratio of PGI/PGII are important detection results. This project uses compound calibrators and quality controls. That is, two different antigens, among them, paired recognition with the antibody in the reagent is a big problem. After years of research, Nanjing Liding Medical Technology Co., Ltd. has greatly improved the adaptation problem of pepsinogen antigen through mutational modification of protein sequence and optimization of storage buffer.

The following uses the pepsinogen (PG) detection kit (latex enhanced immune turbidimetry) developed by Nanjing Liding Medical Technology Co., Ltd. to test the stability of the antigen. The results show that the PGI and PGII antigens are at 37 ℃. Under accelerated investigation for 7 days, the deviation is within ±10%; 2-8 ℃ storage conditions for 2 months, the deviation is within ±10%.


We could not find any corresponding parameters, please add them to the properties table
Online Message
Username used for comment:

Related products

Service hotline

Headquarters: building C6, life science and Technology Innovation Park, Qixia District, Nanjing

E-mail:marketing@leading-med. com


Nanjing Liding Medical Technology Co., Ltd

Mobile station

Nanjing Liding Medical Technology Co., Ltd


Copyright © 2022 Nanjing Liding Medical Technology Co., Ltd  All Rights Reserved       苏ICP备2021032752号-2    SEO